The global melanin-concentrating hormone receptor 1 market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Melanin-concentrating hormone (MCH) is a neuropeptide in the central and peripheral nervous systems that control feeding behaviors and energy metabolism. The major factor contributing to the growth of the market is the increasing prevalence of obesity across the globe. According to the World Health Organization (WHO), an estimated 38.2 million children under the age of 5 years were overweight or obese in 2019. Additionally, the number of overweight children under 5 has increased by nearly 24% since 2000 in Africa. Furthermore,  almost half of the children under 5 who were overweight or obese lived in Asia in 2019. Apart from this, in 2020, an estimated 39 million children under the age of 5 were overweight or obese. Moreover, as per the same source, more than 1.9 billion adults, 18 years and older, were overweight out of which over 650 million were obese in 2016.

Some major players in the market include AstraZeneca Plc, Takeda Pharmaceutical Co., Ltd., and Boehringer Ingelheim GmbH, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2021, Harmony Biosciences Holdings, Inc. announced the acquisition of HBS-102 from ConSynance Therapeutics Inc. HBS-102 is a Melanin Concentrating Hormone Receptor 1 antagonist to offer a novel approach to the treatment of narcolepsy that includes the symptoms of Rapid Eye Movement (REM) sleep dysregulation, such as cataplexy, hallucinations and sleeps paralysis.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- AstraZeneca Plc, Takeda Pharmaceutical Co., Ltd., and Boehringer Ingelheim GmbH, among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Melanin-Concentrating Hormone Receptor 1 Market Report by Segment

By Type

    • ALB-127158(a)

    • AZ-13483342

    • AZD-3857

    • BI-186908

    • Others

By Application 

    • Obesity

    • Inflammatory Bowel Disease

    • Non-Alcoholic Steatohepatitis

    • Others

Global Melanin-Concentrating Hormone Receptor 1 Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa